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Abstract
Real-world data is that collected outside the constraints of controlled clinical trials and is increasingly informing
decision-making in healthcare. The landscape of real-world data in the United Kingdom is set to evolve over the
coming months as the government plans to build on databases currently in place by collecting patient data from
all family practices and linking this information with hospital records. This initiative, called care.data, has the
potential to be an invaluable resource. However, the programme has been criticized on grounds of data privacy,
which has led to an extended delay in its implementation and the expectation that a large number of people will
opt out. Opt-outs may introduce substantial biases to the dataset, and understanding how to account for these
presents a significant challenge for researchers. For the scope and quality of real-world evidence in the United
Kingdom to be realised, and for this information to be used effectively, it is essential to address this challenge.
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Background
Real-world data has been defined by the Association of
the British Pharmaceutical Industry as data collected
outside the controlled constraints of conventional ran-
domised clinical trials to evaluate what is happening in
routine clinical practice [1]. While clinical trials provide
the ‘gold standard’ for establishing treatment efficacy,
they are conducted in small populations under tightly
controlled conditions and thus alone are insufficient to
guide clinical practice [2]. As a result, real-world data
have become important components for healthcare
decision-making [3]. By operating outside the confines
of clinical trials, real-world data can be used to under-
stand treatment effectiveness as well as to provide
insight into patterns of care, long-term drug safety,
healthcare resource utilisation and disease epidemiology.
The routine implementation of electronic medical re-
cords, as well as technological advances that have
allowed for the safe storage and sharing of data, have
provided an unparalleled opportunity to gather and use
real-world data to inform decision-making in healthcare.
With a national health service (NHS) and general practi-
tioners (GP) acting as gatekeepers to secondary care, the
United Kingdom (UK) is uniquely positioned to collate
rich data across its network of healthcare providers.
The Clinical Practice Research Datalink (CPRD) is one
of the UK’s existing primary care databases, which for
over two decades has extracted anonymised medical re-
cords from hundreds of GP practices and has helped to
inform broad issues in patient care. The database cur-
rently has 4.4 million active patients, reflecting 6.9 % of
the UK population [4]. Although working with ‘big data’
requires an understanding of how information is col-
lected and coded, effective strategies can be developed
to recode what are complex raw data for actionable sci-
entific analysis and insight generation. Variation in dis-
ease coding (or failure to code) and differences in
missing data across patients and time, as well as data
not being captured at all, require effortful consideration
on the part of researchers. Nevertheless, the sharing of
CPRD data for research purposes has generated over
1000 peer-reviewed publications, with notable contribu-
tions including work confirming the safety of the mea-
sles, mumps and rubella vaccine [5], fracture risk
associated with thiazolidinediones [6] and work demon-
strating the association between body mass index and
cancer risk [7].
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Care.data – opportunities and challenges
In light of the CPRD’s success and with a view to im-
proving service commissioning across the breadth of the
NHS, the government has planned to extend the reach
of healthcare data collection to all GP practices in the
UK, and to link this information with hospital records
overseen by the Health and Social Care Information
Centre (HSCIC). The initiative, called care.data, was in-
troduced in 2013 under the tagline ‘Better Information
Means Better Care’. The programme will require all GP
practices in the UK to submit data, although each pa-
tient maintains the authority to opt-out and sensitive
data, such as information related to sexual health,
assisted conception, imprisonment or abuse, will not be
extracted. As has been the case with the CPRD, patient
records will be anonymised and shared with approved
third parties after scientific committee approval for ob-
servational research purposes.
Care.data has the potential to be an invaluable source
of real-world data in the UK. The main advantage of the
larger sample size is greater statistical power and the
ability to look at more determinants. This is especially
important for investigating rare diseases or rarer adverse
events from treatments. The database will also overcome
some of the limitations of CPRD by having primary and
secondary care information already linked (although
some information, such as treatments given in hospital,
may remain uncaptured).
Despite the potential value of the database, balancing
the need for well-conducted observational research with
the patient’s right to confidentially has thus far proved
challenging. This was illustrated when the introduction
of the care.data programme in 2013 was met by wide-
spread criticism with concerns raised regarding the shar-
ing of personal data without explicit consent, the
distribution of sensitive data to third parties and data safe-
guarding. Mismanagement and poor communication from
the government regarding these issues resulted in an ex-
tended delay in implementation. In September 2015, the
government commissioned a review into data-sharing
practices in the UK, which will go to public consultation
after the EU ‘Brexit’ referendum in June 2016. When the
care.data programme is eventually resurrected, a large
number of opt-outs should be expected, with initial sug-
gestions showing more than 1 million patients, or 2.2 % of
the NHS’s 56 million patients already choosing to have
their data removed [8]. This number of opt-outs, if occur-
ring non-randomly, has the potential to introduce sub-
stantial biases into the extracted dataset. Understanding
how to identify and account for any biases, as well as the
incomplete variable coverage, presents a significant chal-
lenge for researchers using care.data [9].
Importantly, auto-enrolment with the option to opt-out
offers a substantially more effective and representative
method for participant recruitment than an opt-in ap-
proach. Previous work has shown that recruiting partici-
pants to an observational medical database via an opt-in
strategy compared to an opt-out approach resulted in sig-
nificantly lower recruitment rates and a biased sample,
such that those patients included tended to be healthier
on multiple indicators [10]. Equally, a Canadian stroke
registry requiring explicit consent led to selection biases
in key demographic and clinical characteristics known to
be associated with long-term patient outcomes [11].
When creating a national resource for healthcare data,
an opt-in approach to participant recruitment has the
potential to leave those patients most requiring care
unaccounted for.
The impact of opt-outs on medical records data,
however, has not yet been well-defined. For example, in
a United States birth cohort, the introduction of opt-
out legislation led to significant differences in ethnicity
and maternal age between families who were included
and those who opted-out [12]. This suggests socio-
demographic factors influence decisions to opt out,
which could bias the sample. However, other work in a
cohort being treated for a urinary tract infection found
no differences in age, gender and one clinical character-
istic (urine test) between patients choosing to opt-out
and those included in the final sample [13]. These are,
however, small studies (n < 2000) including only limited
clinical indicators. Clearly, more work is needed to
identify the socio-demographic and clinical characteris-
tics of patients choosing to opt-out in order to under-
stand how this may reduce the value of the data.
Conclusions
Even in view of the large number of expected opt-
outs, it is important to consider that surveys show
most patients are supportive of medical records re-
search [14, 15]. Indeed, Nordic countries have estab-
lished national mandatory health registries with great
success [16, 17]. In these regions, provision of data is
seen as part of the contract for receiving free health-
care, and ethical review committees help ensure data
are handled in a way that maintains patient privacy
[18]. In the UK, any decision to opt-out is likely to
be driven by the patient’s perception of the risks and
benefits involved in sharing their data [15]. Import-
antly, adequately framing arguments around privacy con-
cerns has been shown to generate more positive attitudes
[19]. Therefore, appropriate information needs to be chan-
nelled to groups that may be misinformed or to those pa-
tients who may desire more information. Patients also
need to be engaged, for example, by receiving information
on how their data are being used [20]. However the chal-
lenge of opt-outs are met, adequately addressing the issue
will be essential to ensure the scope and quality of
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observational research generated using care.data are not
compromised, and to continue building on the successes
of existing databases such as the CPRD.
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